Molecular diagnosis in recessive pediatric neurogenetic disease can help reduce disease recurrence in families. by Issa, Mahmoud Y et al.
UC San Diego
UC San Diego Previously Published Works
Title
Molecular diagnosis in recessive pediatric neurogenetic disease can help reduce disease 
recurrence in families.
Permalink
https://escholarship.org/uc/item/6jq364tf
Journal
BMC medical genomics, 13(1)
ISSN
1755-8794
Authors
Issa, Mahmoud Y
Chechlacz, Zinayida
Stanley, Valentina
et al.
Publication Date
2020-05-13
DOI
10.1186/s12920-020-0714-1
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
Molecular diagnosis in recessive pediatric
neurogenetic disease can help reduce
disease recurrence in families
Mahmoud Y. Issa1, Zinayida Chechlacz2, Valentina Stanley2, Renee D. George2, Jennifer McEvoy-Venneri2,
Denice Belandres2, Hasnaa M. Elbendary1, Khaled R. Gaber3, Ahmed Nabil3, Mohamed S. Abdel-Hamid4,
Maha S. Zaki1* and Joseph G. Gleeson2*
Abstract
Background: The causes for thousands of individually rare recessive diseases have been discovered since the
adoption of next generation sequencing (NGS). Following the molecular diagnosis in older children in a family,
parents could use this information to opt for fetal genotyping in subsequent pregnancies, which could inform
decisions about elective termination of pregnancy. The use of NGS diagnostic sequencing in families has not been
demonstrated to yield benefit in subsequent pregnancies to reduce recurrence. Here we evaluated whether genetic
diagnosis in older children in families supports reduction in recurrence of recessive neurogenetic disease.
Methods: Retrospective study involving families with a child with a recessive pediatric brain disease (rPBD) that
underwent NGS-based molecular diagnosis. Prenatal molecular testing was offered to couples in which a molecular
diagnosis was made, to help couples seeking to prevent recurrence. With this information, families made decisions
about elective termination. Pregnancies that were carried to term were assessed for the health of child and mother,
and compared with historic recurrence risk of recessive disease.
Results: Between 2010 and 2016, 1172 families presented with a child a likely rPBD, 526 families received a
molecular diagnosis, 91 families returned to the clinic with 101 subsequent pregnancies, and 84 opted for fetal
genotyping. Sixty tested negative for recurrence for the biallelic mutation in the fetus, and all, except for one
spontaneous abortion, carried to term, and were unaffected at follow-up. Of 24 that genotyped positive for the
biallelic mutation, 16 were electively terminated, and 8 were carried to term and showed features of disease similar
to that of the older affected sibling(s). Among the 101 pregnancies, disease recurrence in living offspring deviated
from the expected 25% to the observed 12% ([95% CI 0·04 to 0·20], p = 0·011).
Conclusions: Molecular diagnosis in an older child, coupled with prenatal fetal genotyping in subsequent
pregnancies and genetic counselling, allows families to make informed decisions to reduce recessive neurogenetic
disease recurrence.
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Background
Congenital malformations account for ~ 20% of infant
mortality and ~ 18% of pediatric hospitalizations [1–3].
Many are recessive disease syndromes that are severe,
untreatable, and adversely affect quality or length of life,
prompting parents to seek prenatal counseling for future
pregnancies. Over 3000 individual genes are currently
linked with Mendelian disease, and this list continues to
grow rapidly [4]. Furthermore, there is growing consen-
sus around standardized interpretation of genetic vari-
ants within a clinical context [5] and diagnostic decision
support software (DDSS) can provide an additional level
of certainty as to pathogenicity [6, 7].
Autosomal recessive diseases account for ~ 26% of se-
vere pediatric conditions undergoing diagnostic sequen-
cing [8], and impart a standard 25% recurrence risk.
Most of these diseases are not evident with fetal ultra-
sound prior to 20 gestational weeks (GW), especially
neurological conditions, since much of human brain de-
velopment occurs after mid-gestation [9, 10]. Next gen-
eration sequencing (NGS) diagnostic approaches are
becoming more common for children with likely reces-
sive diseases [11], and families receiving a molecular
diagnosis for their child could benefit from this informa-
tion for prenatal testing for their subsequent pregnan-
cies. However, there are few reports documenting
population-level effectiveness of fetal genotyping sup-
porting the prevention of disease recurrence through
elective termination of pregnancy (eTOP), and despite
this approach gaining acceptance, each prenatal center
follows its own best-practices.
Here, we leverage family-specific NGS sequencing,
combined with fetal targeted genotyping to measure the
impact of this approach on the eventual disease recur-
rence risk in families, by providing predictive affectation
status information to couples carrying a pregnancy that
were at 25% risk for disease recurrence. We show that
accurate molecular diagnosis in an older affected child
in a family can support prenatal diagnosis (PND) and
genetic counseling for families returning with a subse-
quent pregnancy, which can influence informed deci-
sions about pregnancy termination, ultimately leading to
reduced disease recurrence.
Methods
Study design
We studied the utility of molecular diagnosis in children,
using exome or genome sequencing, on the potential to
support the reduction of disease recurrence in families.
Most recessive pediatric brain disease (rPDB) seen in
our center do not have obvious structural fetal anomal-
ies, rendering fetal imaging sub-optimal for determining
affectation status. We reasoned that, as cases received a
molecular diagnosis, families would be interested in
using this information to distinguish affectation status of
future pregnancies, that could ultimately impact their
decisions about eTOP of fetuses predicted to display dis-
ease. Our framework was based on assessing the poten-
tial impact of NGS diagnosis of an older child on the
recurrence risk in the same family, compared with his-
toric 25% risk. We first validated the use of diagnostic
sequencing, benchmarked diagnostic decision support
software for mutation validation using a signs/symptoms
approach, and utilized this information in counseling
families.
Study cohort
Information on 1172 families that were seen from 2007
to 2016 at a single Egyptian national referral center was
reviewed. These families had 92% reported parental con-
sanguinity and one or more children suffering from a se-
vere undiagnosed neurogenetic disorder. Inclusion
criteria for the study were (a) presence of a likely rPBD
in a child, (b) condition presenting before the age of 2
years and (c) in families with more than one affected
child, both children had a nearly-identical clinical pres-
entation. All living affected children from families meet-
ing study criteria were examined by a clinical geneticist
and a child neurologist with a review of developmental
trajectory, and history of medications, epilepsy, intellec-
tual disability (ID), growth parameters, radiological, elec-
trophysiological (EEG, NCV, EMG), metabolic testing,
and detailed family history. DNA sampling in the form
of blood or saliva was obtained for the entire nuclear
family including all affected and unaffected children and
their parents, and in some cases genetically informative
extended relatives. OMIM features with standard diag-
nostic criteria were used to determine affectation status
of newborn children, as assessed by the neurologist and
geneticist.
Family molecular genetic testing
All 1172 families were subject to exome sequencing be-
tween 2010 and 2016 with a goal of identifying the mo-
lecular cause of the disease in each case. Exome
sequencing was performed on samples from at least one
affected member per family, but usually included two af-
fected children or one affected child and the parents for
singleton cases as described [12].
Exome and genome sequencing
Exome on DNA samples was performed using IDT Ex-
ome capture kit. Hybrid selection libraries covered >
80% of targets at 20x with a mean target coverage of
>80x. The exome data were demultiplexed and each
sample’s sequence was aggregated into a single BAM file.
Genome on DNA samples (500 ng to 1.5 μg) was per-
formed using a PCR-free protocol. These libraries were
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sequenced on the Illumina HiSeq 4000 with 150-bp
paired end reads and target mean coverage of >30x.
A strict set of criteria was used to determine the causal
variant in each family (Section S1). The results of the re-
search sequencing were provided to the medical team
and subsequently to the families only if (a) the variant
was reported as an OMIM gene implicated in a severe
rPBD, (b) met ACMG guidelines as a pathogenic or
likely pathogenic variant [13] and (c) was confirmed in a
clinical laboratory by targeted sequencing. These families
received genetic counseling and were informed about
prenatal or preimplantation genetic diagnosis, gamete
donor, adoption, and treatment/therapy options for sub-
sequent affected children. Families were invited to return
to clinic if they become pregnant in the future.
Genome-phenome validation of molecular diagnosis
All families that received molecular diagnosis and
returned to the genetics clinic while in the first trimester
of pregnancy were followed up in this study. Families in-
terested in prenatal genetic testing were screened by the
team and subsequently consented for PND. For these
families, an additional unbiased comparison between
genotype and phenotype within the clinical context
using SimulConsult® (SC) diagnostic decision support
software (DDSS) was performed (Figs. S1–2). Quantita-
tive assessment of ‘zygosity pertinence’ was calculated, as
a joint probability of a match between signs/symptoms
and gene mutation. Cases with less than 90% pertinence
were excluded from PND. This additional step was per-
formed in order to orthogonally evaluate the pathogenic
variant that was identified using ACMG guidelines.
Integration of genotyping results into clinical practice
Families that opted to conceive again, and succeeded in
becoming pregnant after receiving genetic diagnosis,
returned to clinic between 2013 and 2017 and were of-
fered the possibility of PND under conditions: (a) a sin-
gular genetic cause for the affected child could be
identified with certainty, (b) the genetic cause could be
confirmed through DDSS that incorporated the latest
published gene discoveries and associated disease pheno-
types, (c) the pregnancy was prior to 16 GW at the time
of testing, (d) amniocentesis could be performed at the
clinic with a reported standard risk for all complications
of < 3%, (e) the condition in the older child was consid-
ered untreatable and likely to severely limit lifespan.
Care was taken to avoid maternal blood contamination.
Fetal DNA was extracted and genotyped using Sanger
sequencing for zygosity and segregation in the family in
both parents and all available older children. Assessment
of maternal DNA contamination was performed using
SNP analysis. Analysis of the results were discussed with
the family to convey available options, and risks/benefits
of eTOP in families requesting this information. In all
cases, families had one or more prior affected offspring,
and thus had an appreciation of the natural history of
the disease that potentially impacted their fetus.
Safety
All families with pregnancies received counseling on
risks-to-benefits for prenatal testing procedures. When
amniocentesis was elected, fluid sampling was performed
under ultrasonic guidance at 15–16 GW to minimize
the risk of complications while obtaining fetal genotyp-
ing results as early as possible. Families deciding on
eTOP were referred to certified abortion clinics with
standard low complication rates.
Outcome measures
The primary outcome measure in this study was the af-
fectation status of live-born children that were geno-
typed prenatally through amniocentesis. Phenotype
assessment was performed after birth, at 12 months, and
at 36 months (where possible) and included an evalu-
ation of growth parameters, psychomotor development,
vision, hearing and measures of pertinent features that
distinguished the clinical presentation of the older off-
spring in the family, adjusted for age-of-onset of symp-
toms on a case-by-case basis. Secondary outcome
measures included complications of pregnancy, amnio-
centesis, abortions and deliveries and included spontan-
eous pregnancy termination, Rh-incompatibility, severe
bleeding or loss of amniotic fluid, post-procedure infec-
tions, severe cramping and fetal trauma.
Power calculations
Given the expected 25% recurrence risk for each subse-
quent pregnancy in recessive disease, our study cohort
of 67 births following genetic counseling provided power
of 92.2% (with a two-sided type I error of 5%) to detect a
significant effect of prenatal testing on reduction in the
primary outcome measure, with the observed 67% deci-
sion to terminate pregnancies of an affected fetus corre-
sponding to a change in outcome measure from
predicted 17 out of 67 affected births to observed 8 out
of 67 affected births (Fig. S3).
Statistical analysis
Comparison of categorical variables using the binomial
goodness-of-fit test was performed on a 2 × 2 contin-
gency table with the following cells: expected number of
affected children (25%), expected number of unaffected
children with no prenatal testing (75%), number of ob-
served affected children with prenatal testing, number of
observed unaffected children with prenatal testing.
Negative predictive value (NPV) was calculated accord-
ing to the formula NPV = number true negatives /
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(number true negatives + number false negatives). Posi-
tive predictive value for the full dataset could not be de-
termined due to inability to phenotype eTOPs..
Results
Identification of disease-causing variants in study
participants
In this retrospective study, 1172 families with a likely
rPBD were previously enrolled at a single referral site in
a genetic study aimed at evaluation of the genetic
cause(s) (Fig. 1). Positive family history of consanguinity
was reported in 92% of families. These families pre-
sented with one or more infants or children with a se-
vere neurodevelopmental disease that significantly
impacted health or predicted shortened lifespan. Fully
73% of families already had two or more affected chil-
dren, consistent with a recessive mode of inheritance.
Exome sequencing was performed (see Methods) with
standard clinical interpretation of potentially damaging
variants, including recessive bi-allelic, dominant, X-
linked, de novo, post-zygotic (i.e. somatic) and structural
variants. Through assessment of segregation of the vari-
ant(s) in the family and analysis of splicing in patient cell
lines, evidence that the variant fulfilled ACMG guide-
lines was determined. In 37% of families, lack of a mo-
lecular diagnosis based upon exome led to subsequent
genome sequencing in the trio, which in 7% of cases led
to the identification of a likely disease variant that was
missed from exome, mostly as a result of reduced exome
coverage in certain regions as reported [14].
In 413 families (35.2%), no likely-causative variant
(LCV) could be identified, despite a ‘reflex to trio’
and ‘reflex to genome’ approach (see below), and
were thus excluded from further study. Twenty-one
families (1.7%) displayed variants consistent with
other forms of inheritance (i.e. de novo or X-linked)
and were excluded from study in order to limit the
study to recessive disease. Ultimately in 739 families
(63.0%) a single biallelic LCV was identified in 441
total genes. Of these, 233 families had LCVs in 197
novel genes not implicated in disease prior to the re-
turn of molecular testing results, classified as a ‘vari-
ant of unknown significance’ (VUS) in a ‘gene of
unknown significance’ (GUS). As new disease genes
were constantly published, 88 of the VUS/GUSs were
reinterpreted as pathogenic or likely pathogenic
(ACMG guidelines) within a clinical context upon an-
nual re-review, and the families re-enrolled in the
study (Fig. 1). Similarly, through re-analysis of exome
and genome data, many families with initially negative
sequencing results were subsequently solved according
to ACMG guidelines and re-enrolled in the study.
Fig. 1 Genetic screening for disease-causing biallelic variants. All 1172 families presented with a likely autosomal recessive disorder for genetic
counseling from 2010 through 2016, and underwent exome sequencing. In 413 families, no genetic diagnosis could be made despite ‘reflex to
trio’ and ‘reflex to genome’. In 21 families a disease-causing variant was identified in a gene with a different inheritance pattern (i.e. de novo or X-
linked), and both of these groups were excluded. In 739 families, a single variant was identified that was likely causative. Of these 233 occurred in
genes not previously linked to disease and were initially excluded but in 88, subsequent variant re-interpretation following new publications
allowed families to re-enroll. In all, 526 families with a pathogenic or likely pathogenic variant in a gene previously linked to a disease that was
concordant with the phenotype of the older child or children in the family. (N - number of families)
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Counseling parents for genetic testing results
Five hundred twenty-six families had a pathogenic or a
likely pathogenic variant residing in a gene in which
biallelic variants have been linked to a rPBD with a re-
ported phenotype that closely matched the documented
family phenotype, according to ACMG guidelines. All
clinically relevant variants were confirmed in a clinical
laboratory according to local requirement, confirmed re-
sults results were reviewed by clinical geneticists and
shared with families. Parents of these 526 families were
contacted to convey the sequencing results and for gen-
etic counseling regarding prospective family planning.
Each family was counseled on the prognosis and cur-
rently available treatments and/or supportive therapies
for the disorder, on the available options of PND proce-
dures and the associated risks.
Fetal genotyping
Of 526 families that received molecular diagnoses, 91
(17.3%) conceived again, and returned for prenatal coun-
seling within a four-year time frame between 2013 and
2017 with 101 pregnancies, as 10 families returned with
two pregnancies each. There were 18 (3.4%) families lost
to follow-up. The remaining 417 (79.3%) families upon
follow up, either decided against future pregnancies or
did not succeed in becoming pregnant during this study
period. This was likely in part due to the long interval
between recognition of disease in their child and the
molecular diagnosis (average 2.9 years). There were no
other pregnancies reported by these families in this
study.
For the 101 pregnancies seeking PND, evidence sup-
porting pathogenicity of their variants is provided in
Table S1. Risks and potential false-positive and false-
negative results of PND were discussed prior to
ultrasound-guided amniocentesis. In 17 pregnancies,
PND was declined at that point. Since for many families,
the molecular diagnosis was made several years prior to
the current pregnancy, and more detailed information
became available both on clinical presentation and gen-
etic variants associated with these disorders, re-
evaluation of the data was appropriate. DDSS was used
for those families seeking PND to increase certainty of
genotype to match the phenotype in each case (Table
S1). Due to the possibility that an incorrect provisional
diagnosis of older offspring could have inadvertently in-
fluenced the genetic findings, we opted for a signs/symp-
toms-based DDSS, to provide a quantitative joint
probability for a match (i.e. zygosity pertinence) with the
full NGS variant table (Fig. S1-S2). In all families (84
pregnancies) pertinence was > 95% between signs/symp-
toms and molecular cause (Data S1), and none were ex-
cluded based upon this additional validation step.
Clinical features in families that received fetal genotyping
Of the 74 families that received PND, clinical manifesta-
tions were assigned to one of 7 disease categories, based
on presenting clinical features: (a) microcephaly (MIC),
(b) degenerative brain disease (DBD, including progres-
sive epileptic encephalopathy), (c) lissencephaly/polymi-
crogyria (LIS/PMG), (d) Joubert syndrome and related
disorders (JBTS), (e) cerebellar atrophy (CBA), (f) her-
editary spastic paraplegia (HSP) and (g) ponto-cerebellar
hypoplasia (PCH) (Fig. 2). Example pedigrees, photo-
graphs and brain scan images for each disease category
are shown (Fig. S3).
For each family, available clinical data included signs
and symptoms of general and neurological dysfunction
as well as degree of ID (Table S2). All children presented
with moderate to severe motor delay and over 90% had
profound or severe ID, which was likely to be associated
with congenital syndromes and often involved multisys-
tem abnormalities predicted to limit lifespan. Each case
presented at least two neurological features, with the
majority displaying 4 to 5 features (Fig. S4), consistent
with severe rPBD. Microcephaly and dysmorphic fea-
tures were observed in the majority of cases (> 60%).
Features such as spasticity, ataxia, seizures and develop-
mental regression were noted.
Correlation of fetal genotyping with pregnancy outcomes
Amniocentesis followed by Sanger sequencing of the
variant in the extracted DNA compared with DNA of
the rest of the family, including both parents and all
available children (both affected and unaffected) allowed
for accurate genotyping of all 84 pregnancies. Secondary
outcome measures were all negative for losses of preg-
nancy, extensive bleeding or post-procedural complica-
tions, there was no detectable maternal blood
contamination in collected fetal samples, and no equivo-
cal genotyping results. There were 39 that genotyped as
heterozygous for the pathogenic variant and 21 as
homozygous reference, all predicted to be unaffected by
the disease for which they were tested. Upon follow up,
we found that none of these children showed evidence
of the tested disease at the latest evaluation (Fig. 3 and
Table S3). Among these were one case of a spontaneous
loss of pregnancy that was not attributed to the amnio-
centesis procedure, and one with a skeletal deformity
(absent sternum) at birth that was unrelated to the
phenotype of the affected older sibling, and that
remained otherwise neurologically normal. None of the
children showed any structural deformities attributed to
the amniocentesis procedure. Ten families subsequently
became pregnant again during the study period, and had
a second pregnancy undergo PND (Table S3).
Out of 24 that tested positive for the biallelic patho-
genic variant, 16 ultimately decided on eTOP and 8
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Fig. 2 Classes of clinical diagnoses and percentage of cases with major disease features. a Distribution of clinical diagnoses based on a leading
clinical or morphological feature in 74 of 526 families with identified molecular diagnosis in a child seeking prenatal counseling for one or more
pregnancies. Most common diagnosis was microcephaly followed by degenerative brain diseases (DBD) and lissencephaly/polymicrogyria (LIS/
PMG). b Percent of cases with corresponding symptom. Most cases presented with motor developmental delay and intellectual disability.
Abbreviations: CBA-cerebellar atrophy/hypoplasia, DBD-degenerative brain disease, EPI-epilepsy, HSP-hereditary spastic paraplegia, ID-intellectual
disability, JBST-Joubert Syndrome, LIS-lissencephaly, MIC-microcephaly, PCH-ponto-cerebellar hypoplasia, PMG-polymicrogyria, n.a.-data
not available
Fig. 3 Prenatal genetic testing with workflow and outcome of pregnancies with previously identified disease-causing variant. Families with 101
pregnancies presented at < 16 gestational weeks (GW) from 2013 through 2017. Of these, 17 declined prenatal diagnostics after risk-to-benefit
assessment. Diagnostic decision support software (DDSS) was applied to verify the molecular diagnosis and confirmed the relationship between
genotype and phenotype in the remaining 84 pregnancies that received amniocentesis at 14–16 GW for targeted fetal genotyping. Of these, 24
tested positive and 60 tested negative for the biallelic disease-causing variant. Eight of the 24 pregnancies that tested positive were carried to
term, and in each case the child was diagnosed with a disease concordant with the older affected sibling or siblings. Of 60 pregnancies that
tested negative, one spontaneous miscarriage was excluded from evaluation, and 59 pregnancies were carried to term. In each of these 59 cases,
the child was unaffected at birth and remained unaffected by the time of the last clinical follow-up for the tested disorder. Binomial goodness-of-fit
test showed statistically significant difference in the primary outcome measure (95% CI, 0.04 to 0.20; P = .011) (n - number of individual pregnancies)
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carried the pregnancy to term. None of the 16 women
experienced notable complications of the eTOP. Due to
local customs and medical practice, assessment of fetal
tissue for malformations or genotyping could not be per-
formed. The 8 that were carried to term each returned
to follow up clinic, and each was assessed for clinical
features observed in the older affected sibling(s), accord-
ing to OMIM criteria for each of gene/mutation, in an
age-dependent and organ-specific fashion. Each dis-
played a phenotype concordant with that of the older af-
fected sibling(s) and was ultimately diagnosed as affected
by the same disease (Table S4). Thus, while positive pre-
dictive value (PPV) of PND could not be assessed, nega-
tive predictive value (NPV, i.e. probability that offspring
does not have disease given negative PND) was 100%.
Statistical evidence for reduction of recurrence in families
Tests of significance were limited to the 101 pregnancies
that returned to clinic in molecularly diagnosed cases,
rather than in the full cohort of 1172 cases. Power ana-
lysis to detect significant differences in outcome was
performed by varying the number of pregnancies and
the proportion of predicted affected pregnancies termi-
nated. We determined that a sample size of 80, given
eTOP decision in 70% of affected pregnancies, would
yield > 90% power to detect a significant difference in
outcome from this study (Fig. S5). The observed 12% af-
fected and 88% unaffected for the tested disease live-
births were compared with the expected 25%:75% af-
fected:unaffected, respectively (using normative recessive
inheritance rates) and showed a statistical difference in
the observed percent of liveborns affected by disease
compared with expected (95% CI, 0.04–0.20; P = 0.011).
The observed ratios were also compared with the mea-
sured proportions (i.e. 28.6% tested positive for the bial-
lelic disease-causing variant, whereas we expected 25%),
using a two-tailed binomial test for the goodness-of-fit.
This resulted in a P-value of 0.0017, indicating a signifi-
cant reduction in observed recurrence risk over expected
in this study.
Assessment of decision regret by parents
We assessed parental experiences with their decision
about eTOP at ~ 6months after the predicted due date
for all 24 pregnancies. None of the 8 parents of pregnan-
cies carried to term had feelings of regret about their de-
cision, despite clinical features of disease apparent in
most. These 8 couples cited several reasons why eTOP
was not pursued, including social, logistical, religious or
economic reasons contributing to their decision. None
of these couples were attempting to become pregnant
again at the time of the 6-month follow up, and no fur-
ther pregnancies were observed from these 8 couples.
None of the 16 parents of the eTOPs had feeling of
regret about their decision at follow-up. Several of these
couples were attempting to become pregnant again by
the 6-month visit, and several families had a second
fetus undergo PND during the study period (Table S3).
Discussion
Despite the expansion of NGS into the clinic, and the
improvements in molecular diagnostic rates for neuroge-
netic disease [13, 15] successful utilization of this infor-
mation to improve outcomes or reduce recurrence has
been limited [16, 17]. Using NGS from families recruited
for discovery of genetic causes of severe or lethal rPBDs
allowed for: (a) unbiased assessment of the pathogenicity
of the variant with DDSS, (b) ethical, social, and medical
risk considerations, (c) PND of a genetically susceptible
fetus, (d) referral for eTOP of genetically affected fe-
tuses. Many single-gene disorders do not show gross
structural defects that would be identified by fetal im-
aging in the first trimester, and PND is a valid alterna-
tive to identify fetuses that are predisposed to show
severe disease.
PND could be applied to future families in which the
cause for the index recessive case is determined by tar-
geted panel, exome or genome sequencing. Since the
current diagnostic rates with these techniques vary be-
tween ~ 25 and 60% [8, 18–20], this approach could im-
pact a substantial number of families with recessive
disease that undergo sequencing. Limitations of this
study are that only 91 of the 526 families that received a
molecular diagnosis returned to clinic with a subsequent
pregnancy, which is only 17% of those that could have
benefited. We were also not able to assess the 417 fam-
ilies, where no molecular cause was identified, on
whether family planning decisions would have been dif-
ferent if a molecular cause had been identified. Never-
theless, our results could help to further justify use of
NGS in genetic diseases beyond clinical management of
the affected proband or affected siblings, to include the
potential benefit for future family planning [16]. Even
though reproductive specialists often provide genetic
testing based upon experience, widespread acceptance
by public health authorities and insurance providers
could benefit from future prospective studies demon-
strating NGS implementation that ultimately lead to re-
duced disease recurrence.
Family planning and counseling are some of the most
challenging issues facing the medical team. Decisions ul-
timately lie with the mother or couple, but can be influ-
enced by numerous ethical, social, familial, legal and
logistical considerations. The concepts surrounding con-
sent for PND are evolving in collaboration between fam-
ilies, physicians, sociologists and ethicists to ensure that
couples are provided accurate assessment of risks and
benefits [21]. By limiting this study to a single referral
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center where the practice was consistent among clini-
cians and genetic counselors, families received
consistency in the approach. It will be important to
evaluate psychological issues, inadvertent delays in the
process, and potential barriers to service, to minimize
the likelihood that families cannot receive information
and medical care that they seek.
The NPV of 100% that we observed may not be repre-
sentative for larger applications of this design, taking
into account the 0.1% estimated sequencing error and
the possibility of human error, which would negatively
impact diagnostic accuracy. Additionally, PPV could not
be calculated due to the inability to independently con-
firm the phenotype of fetuses predicted to be affected,
and the absence of clinical features prior to eTOP in
nearly every case. Minimal variability in expressivity of
each condition in each family was observed, where there
were two or more affected children diagnosed prior to
PND, and each of the 8 children later diagnosed as af-
fected displayed features nearly identical to their older
affected sibling(s).
PND performed in the study was targeted to the previ-
ously identified biallelic variant in families with a previ-
ously affected offspring, and as such at best could only
be used to prevent recurrence of disease. The benefit of
this approach is that each family had prior experience
with the disease in their older offspring, which may have
facilitated the decision about subsequent pregnancies.
An imperfect comparison can be made with approaches
that utilize premarital carrier sequencing or fetal NGS in
naïve families even in the presence of congenital malfor-
mations, where experience with the anticipated disease
is minimal or nonexistent.
Although the method chosen for fetal sampling was
amniocentesis, chorionic villus sampling (CVS) is a com-
parable alternative, if available, as it can be performed
earlier than amniocentesis. This would allow for earlier
return of results, provide families with additional time to
consider options, and open up less invasive eTOP op-
tions, while only minimally increasing risk of complica-
tions [22]. Additionally, the variants identified in
probands could be alternatively used in preimplantation
genetic diagnosis (PGD) to reduce recurrence risk in
subsequent pregnancies. PGD is not widely available in
Egypt where this study occurred, limiting its impact, and
suffers its own limitations [23–25].
In our study we focused on direct Sanger sequencing
of the pathogenic allele in the fetus that was previously
identified in an older sibling(s). An alternative approach
utilizing NGS of fetal DNA directly in disease-naïve fam-
ilies would expand the benefit of PND [26], but suffer
from nonpenetrant variants, as was recently reported for
cystic fibrosis or Krabbe diseases [27, 28]. Consanguin-
eous families might especially profit from this approach
due to the higher risk of recessive diseases, or risk of
more than one recessive disease [29].
Recent publications highlight that between 4.9–13% of
cases show two different diseases or disease-causing mu-
tations in the same child [30, 31]. Such occurrence
would reveal a limitation of our approach, unless both
diseases were recognized prior to fetal genotyping. We
did not observe evidence of multiple single-gene disor-
ders in any of our families, probably in part because
families with clinically discordant siblings were excluded.
We observed a skeletal deformity in an otherwise
healthy case newborn, suggesting a second genetic con-
dition, but the genetic origin of the skeletal deformity
was not investigated. Ideally, assessment of all such con-
ditions relevant to the fetus could be performed
simultaneously.
Premarital genetic counseling is seen by some as a su-
perior method to prevent disease, and is in reach for
some common genetic alleles in certain populations [32,
33]. For instance, recessive traits in the Ashkenazi popu-
lation, like Tay-Sachs disease (1:27–1:30 carrier fre-
quency) formed the basis for genetic premarital efforts
that reduced the incidence by > 90% [34]. With an ex-
pansion of NGS accessibility, preconception carrier
screening for the majority of inherited diseases will be
feasible, but will suffer from imperfect predictive power
in many instances. Our study is unique in that it pro-
vides a practical approach for predicting the phenotype
of fetuses in families with a previously affected offspring,
and supports the workflow with the largest to-date
retrospective analysis of outcomes.
Conclusions
Identification of causes through NGS, coupled with pre-
natal fetal genotyping in subsequent pregnancies, allows
families to make informed decisions to reduce recessive
disease recurrence.
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